Clinical Research Directory
Browse clinical research sites, groups, and studies.
Alpha Lipoic Acid in Ulcerative Colitis
Sponsor: Tanta University
Summary
This study aims at evaluating the efficacy and safety of alpha-lipoic acid as adjuvant therapy to mesalamine in patients with mild to moderate ulcerative colitis due to its effect as anti-oxidant and anti-inflammatory drug which can help to improve disease.
Official title: Clinical Study Evaluating the Efficacy and Safety of Alpha-lipoic Acid in Patients With Ulcerative Colitis Treated With Mesalamine
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
60
Start Date
2023-10-01
Completion Date
2025-04-01
Last Updated
2025-02-06
Healthy Volunteers
No
Interventions
"Mesalamine" and "alpha-lipoic acid"
Mesalamine 1000 mg every 8 hrs. + alpha-lipoic acid 600 mg once daily for 3 months
"Mesalamine" and "Placebo"
Mesalamine 1000 mg every 8 hrs. + Placebo once daily for 3 months
Locations (1)
Tanat university hospital
Tanta, Egypt